Baird raised the firm’s price target on LivaNova (LIVN) to $75 from $70 and keeps an Outperform rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees “several potential paths to improved” share performance for the group in 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN:
- LivaNova receives increased CMS reimbursement for VNS Therapy
- LivaNova price target raised to $70 from $65 at Mizuho
- LivaNova price target raised to $70 from $63 at Baird
- LivaNova’s Strategic Growth Plan and OSA Device Commercialization Justify Buy Rating
- LivaNova expects OSA business to be break-even by 2029